Skip to main content

Table 1 Characteristics of all included patients from the National Cancer Database who underwent treatment for retroperitoneal sarcomas

From: Overcoming a travel burden to high-volume centers for treatment of retroperitoneal sarcomas is associated with improved survival

 

Overall cohort (N = 2599)

Age (years, median, IQR)

61 (51–72)

Gender

 Female

1328 (51.9%)

 Male

1231 (48.1%)

Race

 Black

233 (9.1%)

 Other

122 (4.8%)

 White

2204 (86.1%)

Income

 Below median

733 (28.6%)

 Above median

1763 (68.9%)

Insurance status

 None

69 (2.7%)

 Private/government

2300 (89.9%)

 Annual hospital volume (cases, median, IQR)

3 (1–10)

 Travel distance (miles, median, IQR)

14 (4–63)

Charlson-Deyo score

 0

1475 (57.6%)

 1

319 (12.5%)

 ≥ 2

77 (3.0%)

Tumor grade

 1

742 (29%)

 2

318 (12.4%)

 3

1057 (41.3%)

 Neoadjuvant therapy

73 (2.9%)

Extent of surgery

 Local

757 (29.6%)

 Radical

1011 (39.5%)

 Simple

791 (30.9%)

Appropriateness of resection

 R2

89 (3.5%)

 R0/1

1722 (67.3%)

 Hospital length of stay (days, median, IQR)

6 (3–8)

 Radiotherapy

689 (26.9%)

 30-day mortality

95 (3.7%)

 30-day readmission

95 (3.7%)